CAR-T Commercialization Strategies: Views From Novartis And Kite
Executive Summary
At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.
You may also be interested in...
A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas
Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.
Iovance Biotherapeutics CEO On TIL Immunotherapy For Solid Tumors
2018 will be a big year for the clinical stage biotechnology company, which is banking on progressing novel tumor infiltrating lymphocytes for the treatment of solid tumors.
Proving The Value Of Value-Based Deals
As controversy continues over pharmaceutical pricing, more drugmakers are eyeing deals that peg health plan cost to outcomes to boost volume and win formulary placement. But these deals are challenging to construct and to date there is little evidence that they reduce costs for patients.